Mect Corporation

Yoshiko Kirihata

Tomoya Ogawa

Reiji Kannagi

Mamoru Sugimoto

Masaaki Numata

Yukishige Ito

Katsuyoshi Shigeta

A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.9NeuAc terminal. A monoclonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.6Gal.beta. terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer. Hybridomas are prepared which produce antibodies A, B and C. A process for producing the hybridomas is disclosed including the step of fusing a myeloma cell and a B cell (lymphocyte) produced by the immunization of animal using as an antigen, the sialic acid glycolipid containing at least one epitope of the group NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer.

Monoclonal antibody recognizing un-natural ganglioside GD3

Hybridomas which produce monoclonal antibodies specific to an abnormal branched determinant of a synthetic glycolipid antigen and methods of use of the monoclonal antibodies.

Monoclonal antibodies specific for synthetic glycosphingolipids having

Growing community of inventors

Kyoto, Japan

Yoshiko Kirihata